Sign up Australia
Proactive Investors - Run By Investors For Investors

Zelda Therapeutics and Children's Hospital of Philadelphia to study the pharmacology of cannabinoids

Study of cannabinoid disposition in pediatric patients to assist autism research.
Picture of research laboratory
Participation in collaborative autism study in U.S. lifts profile and boosts share price

Zelda Therapeutics Ltd (ASX:ZLD) has entered into a research agreement with Children’s Hospital of Philadelphia (CHOP) relating to the pharmacology of cannabinoids.

The ultimate goal is to describe cannabinoid disposition in pediatric patients, and identify compounds that may demonstrate efficacy in the treatment of pediatric autism.

This news was well received with the company’s shares trading as high as $0.10 in mid-morning trading, up nearly 10% from Friday’s close of $0.091.

This builds on recent share price strength which was partly driven by the company being approved for Australia’s first medical cannabis trial for insomnia.

Read: Zelda Therapeutics approved for Australia’s first medicinal cannabis trial targeting insomnia

The collaborative research with CHOP will focus on autism with an observational trial to better understand the efficacy of treatment in existing patients.

The collaborative group will also be working closely with patient advocacy bodies and licensed growers.

This study will leverage CHOP’s extensive research infrastructure and is designed to capture a number of key efficacy and safety measures including bioanalytical studies.

Study to provide a platform for possible future clinical trials

Participating in this study could lay the foundations for a possible future clinical trial to generate high quality, robust and acceptable data.

The information should then be used to assist in validating the extensive positive anecdotal data amongst patient populations.

Preliminary results expected within six months

This collaboration effectively lifts Zelda’s profile as it will be an important U.S.-based study, focusing on the use of cannabinoids in controlled clinical settings.

The observational study is expected to commence in early 2018, with preliminary results anticipated within six months. 

Join our Crypto, Blockchain and Cannabis Telegram group here
View full ZLD profile View Profile

Zelda Therapeutics Ltd Timeline

Related Articles

June 05 2018
While tricky, the last year has seen Abzena increase its customer engagement with its integrated discovery, development and manufacturing service offering
Skin beauty
April 19 2018
In a note to clients initiating coverage on SkinBio, the joint ‘house’ broker noted that, as the skin microbiome group operates in a new therapeutic area, there is little market data in the sector
September 25 2018
The drug developer had originally to recruit 80 people for the second part of its phase II study of its SNG001 treatment, but it will now assess 120 patients

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use